Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT04513288

ICITRU : Randomized Trial of Immunonutrition With L-citrulline in Patients Hospitalized in Intensive Care for Sepsis or Septic Shock

Led by Rennes University Hospital · Updated on 2024-10-08

130

Participants Needed

5

Research Sites

235 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Immunonutrition in intensive care has not yet demonstrated a beneficial effect on organ failure, the acquisition of nosocomial infections, or mortality. It did not correct for acquired immunosuppression in intensive care patients. Despite numerous methodological problems (use of several pharmaconutrients, very heterogeneous set of patients) and the absence of clinical data, deleterious effects have been attributed to immunonutrition in intensive care, in particular in septic patients and patients in intensive care . Arginine (ARG) is a semi-essential amino acid involved in many immunological mechanisms. It is synthesized in sufficient quantity under normal conditions but quickly becomes insufficient under catabolic conditions such as in severe sepsis. Arginine is not only the precursor of nitrogen monoxide (NO) but also an essential substrate for numerous enzymatic reactions which participate in the maintenance of immune homeostasis, in particular T lymphocyte function. Depletion of the cellular medium in arginine will induce an abnormality in the metabolism of immune cells responsible for a dysfunction of these cells (lymphopenia linked to early apoptosis) and thus expose patients to organ failure and nosocomial infections. It has been found that hypoargininemia in intensive care patients is associated with the persistence of organ dysfunction (SOFA score), the occurrence of nosocomial infections and mortality. Also, it has been demonstrated that in these patients, enteral administration of ARG was not deleterious and increased ornithine synthesis, suggesting a preferential use of ARG via the arginases route, without significant increase in argininaemia or effect on immune functions. L-citrulline (CIT), an endogenous precursor of ARG, constitutes an interesting alternative for increasing the availability of ARG. Sponsor recent data demonstrate that the administration of CIT in intensive care is not deleterious and that it very significantly reduces mortality in an animal model of sepsis, corrects hypoargininemia, with convincing data on immunological parameters such as lymphopenia, which is associated with mortality, organ dysfunction and the occurrence of nosocomial infections. The availability of ARG directly impacts the mitochondrial metabolism of T lymphocytes and their function. Our hypothesis is therefore that CIT supplementation is more effective than administration of ARG in correcting hypoargininemia, reducing lymphocyte dysfunction, correcting immunosuppression and organ dysfunction in septic patients admitted to intensive care.

CONDITIONS

Official Title

ICITRU : Randomized Trial of Immunonutrition With L-citrulline in Patients Hospitalized in Intensive Care for Sepsis or Septic Shock

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with sepsis or septic shock as defined by 2016 guidelines from the European Society of Intensive Care Medicine
  • Initial infection signs started less than 4 days before ICU admission
  • Hospitalized for less than 48 hours before ICU admission
  • Receiving invasive mechanical ventilation with expected duration over 2 days
  • Receiving exclusive enteral nutrition
  • Affiliated with a social security scheme
  • Provided signed consent or included under emergency procedure
Not Eligible

You will not qualify if you...

  • Progressive Sars-CoV2 infection
  • Current pregnancy
  • Morbid obesity with BMI over 40
  • Immunosuppression due to steroids over one month, high-dose steroids, recent radiotherapy or chemotherapy, or proven immune deficiency
  • Contraindications to enteral nutrition such as high flow digestive fistula, intestinal obstruction, small intestine ischemia, or active digestive hemorrhage
  • Participation in other research affecting immune system
  • Receiving immunosuppressive therapy like chemotherapy or high dose corticosteroids (except hydrocortisone for septic shock)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Rennes University Hospital - Medical ICU

Rennes, Brittany Region, France, 35033

Actively Recruiting

2

Rennes University Hospital - Surgical ICU

Rennes, Brittany Region, France, 35033

Terminated

3

Besançon University Hospital

Besançon, France, 25000

Actively Recruiting

4

Le Mans Hospital

Le Mans, France, 72037

Actively Recruiting

5

Tours University Hospital

Tours, France, 37044

Actively Recruiting

Loading map...

Research Team

M

Mathieu Lesouhaitier, MD

CONTACT

J

Jean-Marc Tadié, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here